Rifaximin Prophylaxis for Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome in Cirrhotic Patients
Condition: Spontaneous Bacterial Peritonitis Intervention: Drug: Rifaximin 550 milligram Oral Tablet [XIFAXAN] Sponsor: Samar Atef Sebaweh Mohammed Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 17, 2022 Category: Research Source Type: clinical trials
ASEPTIC: primary antibiotic prophylaxis using co-trimoxazole to prevent SpontanEous bacterial PeritoniTIs in Cirrhosis —study protocol for an interventional randomised controlled trial
DiscussionThis trial will investigate the efficacy, safety, and cost-effectiveness of co-trimoxazole for patients with liver cirrhosis and ascites to determine whether this strategy improves clinical outcomes. Given there are no treatments that improve survival in decompensated cirrhosis outside of liver transplant, if the trial has a positive outcome, we anticipate widespread adoption of primary antibiotic prophylaxis.Trial registrationClinicalTrials.govNCT043955365. Registered on 18 April 2020. Research ethical approval was granted by the Research Ethics Committee (South Central – Oxford B; REC 19/SC/0311) and the Medi...
Source: Trials - September 27, 2022 Category: Research Source Type: clinical trials
Allopurinol Versus Simvastatin to Prevent Complications of Liver Cirrhosis
Conditions: Cirrhosis; Hepatic Encephalopathy; Ascites; Varices; SBP - Spontaneous Bacterial Peritonitis Interventions: Drug: Allopurinol 300 MG; Drug: Simvastatin 40mg; Drug: Placebo Sponsor: Tanta University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2022 Category: Research Source Type: clinical trials
